NK-1 as a melanoma target

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Melanoma cells express neurokinin-1 (NK-1) receptors and substance P (SP).
• SP binding to NK-1 receptors promotes melanoma cell proliferation.
• NK-1 receptor antagonists inhibit melanoma cell proliferation and induce apoptosis.

Purpose of the Study:

• To review the mechanism of action of the SP/NK-1 receptor system in melanoma.
• To examine the role of NK-1 receptor antagonists in human melanoma treatment over the past seven years.

Main Methods:

• Literature review of studies on the SP/NK-1 receptor system and NK-1 receptor antagonists in melanoma.
• Analysis of preclinical data (primarily in vitro) on the antitumor effects of NK-1 receptor antagonists.

Main Results:

• Preclinical studies indicate NK-1 receptor antagonists possess antitumor activity against melanoma.
• The NK-1 receptor antagonist aprepitant, currently in clinical use, demonstrates in vitro antitumor effects on human melanoma.

Conclusions:

• The NK-1 receptor represents a promising therapeutic target for melanoma, particularly for advanced stages (III-IV) lacking effective treatments.
• Clinical trials are warranted to evaluate the efficacy of NK-1 receptor antagonists, such as aprepitant, in human melanoma patients.
• Aprepitant's existing safety data may expedite its clinical evaluation compared to less-studied antagonists.